India is expected to see an 82% increase in consumption of antibiotics in “food animals” from 2,633 tons of antibiotics in 2013, showed a new study.
The move is expected to help doctors practice in different States without seeking different licences across borders and also create a comprehensive database of specialists in different areas of medicine.
The Department of Pharmaceuticals has directed stent importers and domestic manufacturers to maintain their production, import and supply for three months.
At an overall level, these shops contribute about 8-10% of the industry’s sales, almost at par with modern retail, according to industry estimates.
Five months after it was blocked from discontinuing its brands 'Promus Premier' & 'Synergy' in India, Boston Scientific has approached NPPA seeking permission.
The court is expected to hear arguments on Daiichi Sankyo's application to block REL from giving its capital markets subsidiary Rs 500 crore next on Oct 11.
The move is expected to preempt any shortages and ensure uninterrupted supply of a variety of high quality primary and revision knee implants to patients.
Abbott had moved to withdraw Alpine citing that selling the product here was unviable after the maximum prices of all drug-eluting stents were capped at around Rs 29,600.
The company asserted that its decision to withdraw Abbott was based on “low commercial uptake” and this was reflected in the sales figures of these brands in India, according to NPPA.
Justice Jayant Nath has asked the Singhs and two companies they control to submit an affidavit pointing out the status of REL’s sale of Religare Health Insurance to VC firm True North
- No blogs yet have been written by the author, we’re sure the author will contribute one soon